Evaluating the Age Cutoff Criterion for Reporting Benign-Appearing Endometrial Cells in Routine Pap Tests: An 8-Year Retrospective Review

Grada, Zakaria; Paquette, Cherie; Eklund, Claire; Zhang, Cunxian; Sung, C. James; Steinhoff, Margaret M.; Quddus, M. Ruhul

doi:10.1159/000473694

Cited by 6 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have argued that the evaluation of the endometrial cells in the Pap test according to the menopausal state or the presence of symptoms is more valuable in detecting pathologies (8,9). Thereupon, studies have been proposed involving different age limits and various variables (8,(10)(11)(12)(13)(14)(15). In our study, no pathological lesions were found in women between the ages of 40-45 and 46-49, in contrast to women aged 50 and over, most of whom were postmenopausal and had pre-neoplastic and neoplastic lesions.…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of endometrial cells in pap smear of women aged 40 years and older

Keleş¹,

Öztürk²,

Alınca³

et al. 2022

TJPATH

View full text Add to dashboard Cite

Objective: To investigate the histopathological follow-up results in women diagnosed with endometrial cells in the Papanicolaou (Pap) test. Material and Method:Between January 2013 to December 2018, women with endometrial cells on the Pap test were searched from the hospital electronic database. The patients with endometrial cells on the Pap test who underwent further histopathological evaluation and who were followed-up for at least 1 year were enrolled in the study, while those who had a Pap test result other than endometrial cells, were lost during follow-up, or had missing data were excluded.Results: Out of 91,142 Pap smears, 121 (0.1%) cytologically had endometrial cells, and of those 65 cases were eligible for final analysis. The mean age of patients with premalignant/malignant lesions (57.7 ± 2.9) was higher than those with benign lesions (50.1 ± 0.7), with 77% of them in the postmenopausal period. Gynecologic premalignant/malignant lesions were detected in 9 (17.7%) patients including 2 (3.1%) endometrial hyperplasias and 7 (10.8%) endometrial cancers. The menopausal status (p=0.010) and being 50 years and older (p=0.002) were significantly associated with pre-neoplastic or neoplastic changes in patients with endometrial cells. Conclusion:The presence of endometrial cells in Pap tests may be a harbinger of endometrial pathologies, especially at the age of 50 years and over. The menopausal status is another possible determinant in detecting endometrial carcinoma. Further investigation may be suggested in women aged ≥50 years and postmenopausal in the event of endometrial cell detection.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical significance of endometrial cells in pap smear of women aged 40 years and older

Keleş¹,

Öztürk²,

Alınca³

et al. 2022

TJPATH

View full text Add to dashboard Cite

show abstract

“…References were reviewed and no evidence was found to change the 2012 recommendations. [85][86][87][88][89][90][91][92][93]…”

Section: G4 Benign Endometrial Cells In Premenopausal Patients or Bementioning

confidence: 99%

ACOG Publications

2021

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

The guidelines effort received support from the National Cancer Institute and ASCCP. Participating organizations supported travel for their participating representatives. All participating consensus organizations, including the primary funders, had equal and balanced roles in the consensus process including data analysis and interpretation, writing of manuscript, and decision to submit for publication. No industry funds were used in the development of these guidelines. The corresponding authors had final responsibility for the submission decision. The National Cancer Institute (including M.S. and N.W.) receives cervical screening results at reduced or no cost from commercial research partners (Qiagen, Roche, BD, MobileODT, Arbor Vita) for independent evaluations of screening methods and strategies. A.-B.M. is an advisory board member of Merck and GSK. R.S.G. is an ASCCP consultant of Inovio Pharmaceuticals DSMB. W.K.H. is connected with Inovio Pharmaceuticals DSMB. P.E.C. has received HPV tests and assays at a reduced or no cost from Roche, Becton Dickinson, Arbor Vita Corporation, and Cepheid for research. M.H.E. has advised companies and participated in educational activities but does not receive any honoraria or payments for these activities, In some cases, his employer, Rutgers, receives payment for his time for these activities from Papivax, Cynvec, Merck, Hologic, and PDS Biotechnologies. He has been the overall PI or local PI for clinical trials from Johnson&Johnson, Pfizer, Iovance, and Inovio. Funding for these activities is for the research related costs of the trials. The other authors have declared they have no conflicts of interest.

show abstract

Age cutoff for reporting of benign-appearing endometrial cells in Papanicolaou specimens; should it be raised? A 10-year retrospective study from a large county hospital

Hinson

Molberg

Mir

et al. 2019

Journal of the American Society of Cytopathology

View full text Add to dashboard Cite

Evaluating the Age Cutoff Criterion for Reporting Benign-Appearing Endometrial Cells in Routine Pap Tests: An 8-Year Retrospective Review

Cited by 6 publications

References 13 publications

Clinical significance of endometrial cells in pap smear of women aged 40 years and older

Clinical significance of endometrial cells in pap smear of women aged 40 years and older

ACOG Publications

Age cutoff for reporting of benign-appearing endometrial cells in Papanicolaou specimens; should it be raised? A 10-year retrospective study from a large county hospital

Contact Info

Product

Resources

About